JAMP-CANDESARTAN TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

CANDESARTAN CILEXETIL

Pieejams no:

JAMP PHARMA CORPORATION

ATĶ kods:

C09CA06

SNN (starptautisko nepatentēto nosaukumu):

CANDESARTAN

Deva:

32MG

Zāļu forma:

TABLET

Kompozīcija:

CANDESARTAN CILEXETIL 32MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

15G/50G

Receptes veids:

Prescription

Ārstniecības joma:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0135220004; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2012-06-06

Produkta apraksts

1
PRODUCT MONOGRAPH
PR
JAMP-CANDESARTAN
Candesartan Cilexetil Tablets
8 mg, 16 mg and 32 mg
Angiotensin II
AT
1
Receptor Blocker
JAMP PHARMA CORPORATION
1310
rue
Nobel
Boucherville,
Québec J4B 5H3
Control No. : 229652
Date of Approval:
April 17, 2020
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE REACTIONS
..................................................................................................
8
DRUG INTERACTIONS
........................................................................................................
14
DOSAGE AND
ADMINISTRATION.........................................................................
18
O V E R D O S A GE
..........................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................... 21
STORAGE AND STABILITY
................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
.................................................................................25
PHARMACEUTICAL INFORMATION
25
CLINICAL TRIALS
..........................................................................................................
26
DETAILED PHARMACOLOGY
.................................................................................
30
TO X IC OLO G Y
....................................................